ResMed Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 6/6

ResMed şirketinin toplam hissedar öz sermayesi $5.2B ve toplam borcu $677.5M olup, bu da borç-öz sermaye oranını 13% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla $7.2B ve $2.0B dir. ResMed 'in FAVÖK'ü $1.5B faiz karşılama oranı 41 dur. Şirketin $442.6M tutarında nakit ve kısa vadeli yatırımları bulunmaktadır.

Anahtar bilgiler

13.0%

Borç/özkaynak oranı

US$677.47m

Borç

Faiz karşılama oranı41x
NakitUS$442.58m
EşitlikUS$5.20b
Toplam yükümlülüklerUS$2.03b
Toplam varlıklarUS$7.22b

Son finansal sağlık güncellemeleri

Recent updates

Shareholders May Not Be So Generous With ResMed Inc.'s (NYSE:RMD) CEO Compensation And Here's Why

Nov 13
Shareholders May Not Be So Generous With ResMed Inc.'s (NYSE:RMD) CEO Compensation And Here's Why

We Think ResMed (NYSE:RMD) Can Manage Its Debt With Ease

Nov 01
We Think ResMed (NYSE:RMD) Can Manage Its Debt With Ease

Here's Why We Think ResMed (NYSE:RMD) Might Deserve Your Attention Today

Oct 20
Here's Why We Think ResMed (NYSE:RMD) Might Deserve Your Attention Today

ResMed Inc.'s (NYSE:RMD) Intrinsic Value Is Potentially 47% Above Its Share Price

Oct 08
ResMed Inc.'s (NYSE:RMD) Intrinsic Value Is Potentially 47% Above Its Share Price

Why ResMed's Rally Is Just Getting Started

Sep 18

ResMed Inc.'s (NYSE:RMD) Earnings Haven't Escaped The Attention Of Investors

Sep 13
ResMed Inc.'s (NYSE:RMD) Earnings Haven't Escaped The Attention Of Investors

ResMed (NYSE:RMD) Is Increasing Its Dividend To $0.53

Aug 05
ResMed (NYSE:RMD) Is Increasing Its Dividend To $0.53

Does ResMed (NYSE:RMD) Have A Healthy Balance Sheet?

Jul 29
Does ResMed (NYSE:RMD) Have A Healthy Balance Sheet?

Returns On Capital Are A Standout For ResMed (NYSE:RMD)

Jul 15
Returns On Capital Are A Standout For ResMed (NYSE:RMD)

ResMed: Asymmetrical Value Opportunity With High Prospect Of Re-Rating

Jul 03

An Intrinsic Calculation For ResMed Inc. (NYSE:RMD) Suggests It's 33% Undervalued

Jul 02
An Intrinsic Calculation For ResMed Inc. (NYSE:RMD) Suggests It's 33% Undervalued

ResMed (NYSE:RMD) Seems To Use Debt Quite Sensibly

Apr 30
ResMed (NYSE:RMD) Seems To Use Debt Quite Sensibly

Earnings Beat: ResMed Inc. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models

Apr 30
Earnings Beat: ResMed Inc. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models

ResMed Inc.'s (NYSE:RMD) Popularity With Investors Is Clear

Apr 18
ResMed Inc.'s (NYSE:RMD) Popularity With Investors Is Clear

With EPS Growth And More, ResMed (NYSE:RMD) Makes An Interesting Case

Mar 22
With EPS Growth And More, ResMed (NYSE:RMD) Makes An Interesting Case

Capital Investments At ResMed (NYSE:RMD) Point To A Promising Future

Mar 10
Capital Investments At ResMed (NYSE:RMD) Point To A Promising Future

An Intrinsic Calculation For ResMed Inc. (NYSE:RMD) Suggests It's 30% Undervalued

Feb 12
An Intrinsic Calculation For ResMed Inc. (NYSE:RMD) Suggests It's 30% Undervalued

Why ResMed Is One Of My Top Picks In 2024

Jan 22

A First Look At ResMed

Jan 09

ResMed Inc.'s (NYSE:RMD) Share Price Could Signal Some Risk

Dec 20
ResMed Inc.'s (NYSE:RMD) Share Price Could Signal Some Risk

Why You Should Care About ResMed's (NYSE:RMD) Strong Returns On Capital

Dec 06
Why You Should Care About ResMed's (NYSE:RMD) Strong Returns On Capital

Shareholders May Find It Hard To Justify Increasing ResMed Inc.'s (NYSE:RMD) CEO Compensation For Now

Nov 10
Shareholders May Find It Hard To Justify Increasing ResMed Inc.'s (NYSE:RMD) CEO Compensation For Now

Are Investors Undervaluing ResMed Inc. (NYSE:RMD) By 41%?

Nov 01
Are Investors Undervaluing ResMed Inc. (NYSE:RMD) By 41%?

ResMed: Weight-Loss Drug Worries Provide Buying Opportunity

Oct 28

ResMed: Stock Re-Rating To 20x Forward P/E Is A Buy Opportunity

Sep 12

ResMed Has Become A Steal (Rating Upgrade)

Aug 10

ResMed's (NYSE:RMD) Shareholders Will Receive A Bigger Dividend Than Last Year

Aug 07
ResMed's (NYSE:RMD) Shareholders Will Receive A Bigger Dividend Than Last Year

ResMed (NYSE:RMD) Has Some Way To Go To Become A Multi-Bagger

Jul 30
ResMed (NYSE:RMD) Has Some Way To Go To Become A Multi-Bagger

Here's Why We Think ResMed (NYSE:RMD) Might Deserve Your Attention Today

Jul 16
Here's Why We Think ResMed (NYSE:RMD) Might Deserve Your Attention Today

Compound Your Wealth With ResMed

Jul 04

A Look At The Fair Value Of ResMed Inc. (NYSE:RMD)

Jul 02
A Look At The Fair Value Of ResMed Inc. (NYSE:RMD)

We Think ResMed (NYSE:RMD) Can Stay On Top Of Its Debt

May 26
We Think ResMed (NYSE:RMD) Can Stay On Top Of Its Debt

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: RMD 'nin kısa vadeli varlıkları ( $2.6B ) kısa vadeli yükümlülüklerini ( $904.1M ) aşıyor.

Uzun Vadeli Yükümlülükler: RMD şirketinin kısa vadeli varlıkları ( $2.6B ) uzun vadeli yükümlülüklerini ( $1.1B ) aşmaktadır.


Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: RMD 'nin net borç/öz sermaye oranı ( 4.5% ) tatmin edici olarak değerlendirilmektedir.

Borcun Azaltılması: RMD 'nin borç/öz sermaye oranı son 5 yılda 57.6% seviyesinden 13% seviyesine düştü.

Borç Kapsamı: RMD 'nin borcu işletme nakit akışı ( 212.6% ) tarafından iyi bir şekilde karşılanmaktadır.

Faiz Kapsamı: RMD 'in borcuna ilişkin faiz ödemeleri EBIT ( 41 x kapsam) tarafından iyi bir şekilde karşılanmaktadır.


Bilanço


Sağlıklı şirketleri keşfedin